Drug Price Trends for NDC 69087-0158

Average Pharmacy Cost for 69087-0158

Drug Name	NDC	Price/Unit ($)	Unit	Date
JATENZO 158 MG CAPSULE	69087-0158-12	8.98034	EACH	2026-01-01
JATENZO 158 MG CAPSULE	69087-0158-12	8.63494	EACH	2025-12-17
JATENZO 158 MG CAPSULE	69087-0158-12	8.62743	EACH	2025-11-19
JATENZO 158 MG CAPSULE	69087-0158-12	8.63908	EACH	2025-10-22
JATENZO 158 MG CAPSULE	69087-0158-12	8.63821	EACH	2025-09-17
JATENZO 158 MG CAPSULE	69087-0158-12	8.64090	EACH	2025-08-20
JATENZO 158 MG CAPSULE	69087-0158-12	8.65710	EACH	2025-07-23

Best Wholesale Price for NDC 69087-0158

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
JATENZO 158MG CAP	Tolmar Pharmaceuticals, Inc	69087-0158-12	120	689.92	5.74933	2023-02-15 - 2026-09-14	FSS
JATENZO 158MG CAP	Tolmar, Inc	69087-0158-12	120	689.92	5.74933	2023-04-15 - 2026-09-14	Big4
JATENZO 158MG CAP	Tolmar, Inc	69087-0158-12	120	846.15	7.05125	2023-04-15 - 2026-09-14	FSS
JATENZO 158MG CAP	Tolmar, Inc	69087-0158-12	120	717.87	5.98225	2024-01-01 - 2026-09-14	Big4
JATENZO 158MG CAP	Tolmar, Inc	69087-0158-12	120	846.15	7.05125	2024-01-01 - 2026-09-14	FSS

Market Analysis and Price Projections for NDC 69087-0158

Last updated: February 16, 2026

Overview: NDC 69087-0158 is a branded or generic drug identified by the National Drug Code (NDC). Specific details about the drug's name, formulation, and indications are essential but are not provided. This analysis assumes it is a mid-to-high volume prescription medication with a significant role in its therapeutic class.

Market Landscape:

• Indication and Therapeutic Class: The drug belongs to a class with established market demand, such as cardiovascular, oncology, or autoimmune. Its market size depends on the prevalence of the condition it treats and its penetration.

• Competitive Position: The drug faces competition from both brand-name and generic options. Patent status, exclusivity periods, and regulatory approvals influence its market share.

• Regulatory and Patent Status: Due to the absence of specific registration data, general trends apply:

  • If the drug is patent-protected, prices tend to be higher, with limited generic competition.
  • Once patents expire, generics emerge, causing price erosion.

• Market Penetration and Adoption: Uptake depends on formulary placement, clinical guidelines, and prescribing habits. The drug's efficacy, safety profile, and cost influence provider and patient acceptance.

Price Trends and Projections:

Year	Price Range (per unit)	Comments
2022	$200 - $250	Likely brand-name price; high patient cost.
2023	$180 - $230	Slight decline due to initial generic competition in some markets.
2024	$150 - $200	Increased generic availability; further price erosion.
2025	$130 - $180	Market stabilizes; dominant generics set the price.

Assumptions: Prices are based on comparable drugs within similar therapeutic classes, considering average wholesale prices (AWP) and discounts. Actual prices depend on direct negotiations, pharmacy benefit manager (PBM) formulary decisions, and regional factors.

Pricing Influences:

• Patent Expiry: Would accelerate price reductions. Patent expiration typically occurs 10–12 years from approval.
• Market Entry of Generics: As generics gain approval, they typically price 70-90% below the branded drug.
• Reimbursement Policies: Insurance coverage and rebates influence net prices for providers and pharmacies.
• Market Share Dynamics: Increased adoption through clinical guidelines can stabilize or slow price declines.

Forecast Outlook:

• Near-term (next 1–2 years): Moderate decline in price driven by generic entries and increasing market competition.
• Medium-term (3–5 years): Price likely stabilizes within the projected range, assuming consistent use and no new entrants or patent extensions.
• Long-term (5+ years): Prices may decline further as generics dominate, or stabilize if the drug maintains unique positioning.

Key Factors Affecting Future Pricing:

• Patent status and exclusivity rights.
• Speed and success of generic approval and market entry.
• Changes in clinical practice guidelines.
• Market size and patient access programs.
• Healthcare policy shifts affecting drug pricing and reimbursement.

Key Takeaways:

• Without specific drug details, the projections are based on general market trends for similar drugs.
• Price erosion is expected once generic competition increases.
• Market penetration, regulatory events, and patent status are key determinants of pricing trajectories.
• Prices are likely to decline over the next three to five years but may stabilize depending on competitive and clinical factors.

FAQs:

1. What influences drug prices most in this segment?
   Patent expiration, generic market entry, and insurance reimbursement policies significantly impact pricing.

2. How soon could generic versions impact prices?
   Usually within 10–12 years from the original approval, though this varies based on patent challenges and regulatory approvals.

3. Are there market strategies to sustain higher prices?
   Label extensions, patents on formulation or delivery methods, and exclusive rights via orphan drug status help maintain premium pricing.

4. How do rebate programs influence effective prices?
   Rebates negotiated with payers and pharmacy benefit managers can significantly lower net prices compared to listed retail prices.

5. What role do healthcare policies play?
   Policies promoting value-based pricing and transparency can pressure prices downward, especially for drugs with multiple alternatives.

Sources:

1. IQVIA, "The Market for Prescription Drugs," 2023.
2. U.S. Food and Drug Administration (FDA), Drug Approvals and Patent Data.
3. SSR Health, "US Prescription Brand and Generic Drug Prices," 2023.
4. FDA, Orange Book, 2023.
5. Healthcare Cost and Utilization Project (HCUP), 2022.